Natera (NTRA) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Natera (NASDAQ:NTRA) from a buy rating to a hold rating in a research report report published on Wednesday.
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
Other analysts have also recently issued reports about the company. Piper Jaffray Companies lifted their price objective on Natera to $27.00 and gave the company an overweight rating in a research report on Thursday, August 9th. BidaskClub cut Natera from a strong-buy rating to a buy rating in a research report on Thursday, August 30th. TheStreet cut Natera from a c- rating to a d+ rating in a research report on Tuesday, October 9th. Craig Hallum lifted their price objective on Natera from $23.00 to $30.00 and gave the company a buy rating in a research report on Thursday, August 9th. Finally, Cowen reaffirmed a buy rating and set a $30.00 price objective on shares of Natera in a research report on Friday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $28.25.
Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). The firm had revenue of $65.30 million for the quarter, compared to the consensus estimate of $66.42 million. Natera had a negative net margin of 58.00% and a negative return on equity of 2,569.52%. The business’s revenue was up 16.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.51) earnings per share. As a group, equities research analysts anticipate that Natera will post -2.1 earnings per share for the current year.
In other news, COO Steven Leonard Chapman sold 35,000 shares of the business’s stock in a transaction that occurred on Friday, October 12th. The stock was sold at an average price of $20.66, for a total value of $723,100.00. Following the sale, the chief operating officer now directly owns 24,240 shares of the company’s stock, valued at approximately $500,798.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.27, for a total value of $4,045,008.09. Following the completion of the sale, the insider now directly owns 481,975 shares in the company, valued at $11,697,533.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,014,988 shares of company stock worth $48,674,710. Insiders own 13.18% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Tygh Capital Management Inc. raised its holdings in Natera by 32.3% in the 2nd quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock worth $5,647,000 after acquiring an additional 73,301 shares during the last quarter. Prescott Group Capital Management L.L.C. purchased a new position in Natera in the 2nd quarter worth approximately $572,000. EAM Investors LLC purchased a new position in Natera in the 2nd quarter worth approximately $3,868,000. Swiss National Bank raised its holdings in Natera by 27.1% in the 2nd quarter. Swiss National Bank now owns 60,900 shares of the medical research company’s stock worth $1,146,000 after acquiring an additional 13,000 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in Natera in the 2nd quarter worth approximately $928,000. 68.11% of the stock is currently owned by hedge funds and other institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.